Omeros Corporation's stock fell 19.12% after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the company's marketing application for narsoplimab, a treatment for transplant-associated thrombotic microangiopathy. This setback led to a securities fraud investigation by Pomerantz LLP on behalf of Omeros investors, alleging possible misconduct by the company and its officers. The outcome could impact investor confidence and the company's future drug approval efforts.
US spot Ethereum ETFs attracted $189.15 million in net inflows on August 19, marking the largest single-day inflow since October 2025. BlackRock's ETHA fund accounted for about 65% of this inflow, signaling renewed institutional interest in ether. Au...
Japan Tobacco is rated a BUY as it trades at a 19% discount to Philip Morris despite similar expected earnings growth. The company is expected to outperform peers due to strong operating income growth, market share gains, volume increases, and price ...
Jim Cramer recently said he sold all his Bitcoin due to concerns about quantum computing potentially breaking Bitcoin's cryptography, citing IBM CEO's warning. However, days later on his show Mad Money, he advised a caller to buy Bitcoin instead of a...
Rosen Law Firm is investigating a class action lawsuit against UP Fintech Holding Limited following allegations that the company provided misleading business information to investors. The investigation follows a Reuters report about China's crackdown...
John B. Sanfilippo & Son (JBSS) saw its stock fall about 7% after Q4 results were affected by high oil prices and a one-time product recall. Despite these setbacks, volume growth returned, indicating steady demand and operational improvement. The com...
